Can Pfizer Avoid Liability for Depo-Provera Brain Tumor Risks?

Federal Preemption Defense Emerges as Key Battle in Growing MDL Against Birth Control Shot Manufacturer

Pfizer faces mounting legal pressure from over 550 lawsuits alleging its contraceptive injection Depo-Provera causes brain tumors, with the pharmaceutical giant now arguing it cannot be held liable because the FDA rejected proposed warning label updates about meningioma risks. The multidistrict litigation (MDL) consolidated in the Florida federal court represents women who developed intracranial meningiomas after using the birth control shot, with plaintiffs claiming Pfizer knew about the tumor risks for decades but failed to warn American consumers. The company's federal preemption defense strategy, filed in August 2025, seeks to dismiss the entire litigation based on FDA regulatory decisions, setting up a pivotal legal battle that could determine whether thousands of affected women can pursue compensation.

Key Facts

• Over 550 Depo-Provera brain tumor lawsuits have been consolidated into MDL 3140 in the Northern District of Florida.

• Studies show women using Depo-Provera for more than one year face a 3.5 to 5.5 times greater risk of developing meningioma brain tumors.

• Pfizer claims that the FDA's rejection of label changes blocks state law failure-to-warn claims through federal preemption.

• Warning labels about meningioma risks have been updated in Europe, Canada, and South Africa, but not in the United States.

• The FDA plans to establish cadmium and arsenic limits for baby food by the end of 2025, though this is unrelated to the Depo-Provera litigation.

What Is the Connection Between Depo-Provera and Brain Tumors?

Scientific research has established a significant link between long-term Depo-Provera use and the development of meningiomas, typically non-cancerous but potentially debilitating brain tumors. A March 2024 study published in the British Medical Journal (BMJ) found that women who use Depo-Provera shots for at least one year are five times more likely to develop meningioma brain tumors compared to those using combination birth control pills. The risk appears to increase with duration of use, with some lawsuits claiming that prolonged exposure results in a 555% increased risk of developing intracranial meningiomas.

The active ingredient in Depo-Provera, medroxyprogesterone acetate (MPA), is a synthetic version of progesterone that has been linked to tumor growth. Research published in Neuro-Oncology Advances in June 2023 demonstrated that spinal meningioma growth is connected to progesterone hormones, providing a biological mechanism for the observed increased tumor risk in Depo-Provera users.

Why Hasn't Pfizer Updated Warning Labels in the United States?

Despite acknowledging awareness of the meningioma risk to The Guardian in March 2024, Pfizer has not updated Depo-Provera's warning labels in the United States to include the risk of brain tumors. The company stated it was "in the process of updating product labels and patient information leaflets with appropriate wording" in collaboration with regulatory agencies, yet American consumers remain uninformed through official product labeling.

This stands in stark contrast to international regulatory actions. Warning labels in Europe, Canada, and South Africa have been updated to reflect the risks of meningioma, with Canada implementing changes as early as 2015. The disparity between international and domestic labeling practices forms a central element of the litigation, with plaintiffs arguing that Pfizer prioritized profits over patient safety by maintaining different safety standards for American consumers.

How Is Pfizer Using Federal Preemption as a Defense Strategy?

Pfizer's primary defense strategy relies on the doctrine of federal preemption, arguing that FDA regulations override state law failure-to-warn claims. The company filed a motion for summary judgment in August 2025, claiming it cannot be held liable for failing to warn about meningioma risks because the FDA rejected a proposed label change in 2024 that would have included this information.

The Legal Standard for Preemption

Under controlling case law from Wyeth v. Levine, pharmaceutical companies must demonstrate that the FDA clearly and definitively rejected the specific warning that plaintiffs claim should have been added. A general refusal to accept vague or broadly worded language does not meet this demanding standard. Pfizer must prove it was impossible to comply with both federal and state law requirements regarding warning labels.

Plaintiffs' attorneys argue that Pfizer could have used the Changes Being Effected (CBE) process to strengthen warnings independently and that the FDA never foreclosed the specific disclosure at issue. They contend that Pfizer's preemption argument fails because the company has not provided supporting documentary evidence of its communications with the FDA, including the requested label change, scientific support provided, or the FDA's denial letter.

What Types of Damages Are Women Seeking in These Lawsuits?

Women diagnosed with meningiomas after Depo-Provera use are pursuing compensation for various damages through the consolidated MDL. These include past and future medical expenses related to brain tumor treatment, often involving invasive surgery and lifelong monitoring requirements. Lost wages and diminished earning capacity represent significant financial impacts, particularly for women who experienced permanent disabilities from their tumors.

Pain and suffering damages address the physical and emotional trauma of brain tumor diagnosis and treatment. Some plaintiffs report permanent complications, including blindness, chronic incontinence, constant dizziness, and extreme fatigue. The lawsuits also seek punitive damages based on allegations that Pfizer deliberately withheld safety information while knowing about the tumor risks for decades.

Who Qualifies to File a Depo-Provera Brain Tumor Lawsuit?

Eligibility for joining the Depo-Provera MDL requires meeting specific criteria related to medication use and medical diagnosis. Women must have received multiple Depo-Provera injections, typically for at least one year, though some cases involve decades of use. A confirmed diagnosis of intracranial meningioma following Depo-Provera use is essential for pursuing a claim.

Statute of Limitations Considerations

The timeline for filing a lawsuit varies by state, but generally starts from the date of tumor diagnosis. However, the discovery rule may extend this deadline, with the clock starting when a patient could reasonably connect their tumor to Depo-Provera use. Attorneys argue that without proper warning labels, patients could not have reasonably made this connection earlier, potentially extending filing deadlines for many women.

Some states, including California and Massachusetts, recognize innovator liability, allowing patients harmed by generic versions to sue the brand-name manufacturer. This doctrine holds Pfizer responsible even for injuries from generic medroxyprogesterone acetate products, based on the "duty of sameness" requiring generic drugs to carry identical warning labels.

What Is the Current Status of the Depo-Provera MDL?

The Depo-Provera litigation continues to expand rapidly, with nearly 100 new plaintiffs joining between June and July 2025 alone. The MDL is centralized in the Northern District of Florida under MDL No. 3140, titled "IN RE: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation." Case management conferences are scheduled throughout 2025 to coordinate discovery and pretrial proceedings.

Generic manufacturer defendants, including Greenstone and Viatris, have faced sanctions threats for missing court-ordered deadlines to submit non-involvement affidavits. The judge's strict enforcement of procedural requirements signals an intent to move the litigation forward efficiently despite its complexity.

How Does Depo-SubQ Provera Factor Into the Design Defect Claims?

Beyond failure-to-warn claims, plaintiffs assert strong design defect arguments centered on the availability of Depo-SubQ 104 Provera, a safer alternative that Pfizer already manufactures but barely markets in the United States. This subcutaneous formulation contains only 104 mg of medroxyprogesterone acetate compared to the standard 150 mg intramuscular dose, while maintaining equal contraceptive efficacy on the same quarterly injection schedule.

The existence of this lower-dose alternative undermines potential preemption defenses for design defect claims, as these are not subject to the same federal regulatory constraints as warning label disputes. Plaintiffs argue that Pfizer's decision to continue promoting the higher-dose formulation despite having a safer alternative available demonstrates deliberate indifference to patient safety.

What Previous Depo-Provera Litigation Has Occurred?

This is not Pfizer's first legal battle over Depo-Provera safety concerns. The company previously faced lawsuits alleging the birth control shot causes bone density loss, leading to osteopenia and osteoporosis. In response to these concerns, Pfizer added a black box warning about bone mineral density loss to Depo-Provera's label in 2004, though only after significant pressure.

Pfizer was ordered to pay more than $2 million in settlements for failing to properly warn patients about the risks to their bone density. Additionally, Depo-Provera pseudotumor cerebri lawsuits claimed the shot could cause increased brain pressure mimicking tumor symptoms, though no publicly announced settlements or jury verdicts resulted from that litigation.

What Role Do International Studies Play in the Litigation?

The March 2024 BMJ study serves as crucial scientific evidence for plaintiffs, providing peer-reviewed, large-scale data that demonstrate an increased risk of meningioma in Depo-Provera users. This research involved a comprehensive analysis of medroxyprogesterone acetate use and established clear risk ratios that plaintiffs' attorneys use to support causation arguments.

The study's findings strip away defense arguments about lacking U.S. population data, providing evidence that the injectable form of medroxyprogesterone carries unique risks not associated with other contraceptives. When applied to the tens of millions of women who have used Depo-Provera over decades, even the "small" individual risk translates to thousands of preventable tumors requiring surgery and lifelong monitoring.

The Path Forward for Affected Women

As the Depo-Provera MDL progresses through discovery, the resolution of Pfizer's preemption defense will likely determine the litigation's trajectory. If the court rejects preemption arguments, the cases could proceed to bellwether trials that would establish settlement values for the broader group of plaintiffs. The growing number of cases and international regulatory actions supporting the link between meningioma and the plaintiffs' position strengthen their position.

Women currently using Depo-Provera should discuss alternative contraceptive options with their healthcare providers, particularly if they have used the injection for extended periods. Those diagnosed with meningiomas after Depo-Provera use should preserve medical records documenting their contraceptive history and tumor diagnosis while consulting with attorneys experienced in pharmaceutical litigation to understand their legal options before statutes of limitations expire.